Commercial adoption
Pre-revenue; demand for the platform is unproven.
Mitigant: Staged spend against milestones.
Risk factors
What can go wrong — and what is verified.
Risk factors
What can go wrong — and what is verified.
We publish the risks and the evidence status of every claim. The verification table is the source of truth.
Performance translation
Backtests may not persist in live markets.
Mitigant: Separate reporting and hard risk limits.
Key person
The founder is central to research and product.
Mitigant: Documentation, hiring plan and advisory.
Regulatory
Licensing and marketing rules vary by jurisdiction.
Mitigant: Counsel, eligibility gates and jurisdictional limits.
Technology & data
Vendor, data and hardware dependence.
Mitigant: Multi-source data and redundant infrastructure.
Liquidity & IPO
No assurance of a sale, dividend or listing.
Mitigant: Long horizon and alternative exit routes.
Appendix — what is verified, and what is not
Updated before every distribution| Claim | Status | Evidence |
|---|---|---|
| 20+ years backtested | Founder-reported | Methodology memo in data room |
| Live internal use since 2024 | Founder-reported | Internal logs in data room |
| ~20,000 trading community | Founder-reported | Channel and cohort verification pack |
| CTP relationship | Relationship | Not contracted; terms to be documented |
| Hedge-fund adoption | Discussions | No signed licences claimed |
| Revenue | Pre-revenue | No customer contracts |
| AMD Alveo pricing | Public listing | CDW / DatorPro, November 2026 |
| 2030 revenue case | Illustrative | Driver-based model in data room |
| 2030 listing | Target | Not a commitment; subject to market conditions |
Next
Investor access